Molecular Basis of Flavivirus Cross-Neutralization by Human Antibodies
Molecular Basis of Flavivirus Cross-Neutralization by Human Antibodies
批准号:
9790956
负责人:
Aravinda M. DeSilva
金额:
$57.32万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-08-05 至 2023-08-31
关键词:
AffinityAmericasAntibodiesAntibody RepertoireAntibody ResponseAsiaAttenuatedBindingBlood specimenComplexDengueDengue Hemorrhagic FeverDengue InfectionDengue VaccineDengue VirusDevelopmentEpitopesEvaluationExposure toFlavivirusFlavivirus InfectionsHealthHumanImmuneImmunityIndividualInfectionLaboratoriesLatin AmericaMemory B-LymphocyteModelingMolecularMutatePatternPlasma CellsPrimary InfectionPropertyReportingSamplingSecondary toSerotypingSerumSpecificitySpecimenStructureSurfaceTestingVaccinesViralVirionZIKV infectionZika Viruscross reactivitydesignenv Gene Productsexposed human populationmosquito-borneneutralizing antibodynext generationnovelnovel vaccinespreventresponsesecondary infection
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Abstract
Zika virus (ZIKV) and the four-dengue virus (DENV) serotypes are emerging mosquito-borne flaviviruses that
pose serious threats to human health. People exposed to primary DENV infections develop long-term serotype-
specific neutralizing and protective antibodies (Abs). Individuals exposed to secondary DENV infections with a
new serotype develop a novel class of cross neutralizing and protective Abs that are even effective against
serotypes not previously encountered by the individual. While the molecular properties of type-specific human
neutralizing Abs have been well-defined, little is known about the origin and properties of DENV cross-
neutralizing Abs induced after secondary infection. In this project, we will use an established human challenge
model of secondary DENV infection to test the hypothesis that secondary infections activate and expand memory
B cells from primary infections to generate somatically mutated Abs that bind with high affinity to epitopes that
are conserved between DENV serotypes (Specific Aim 1). We will also define the molecular specificity and
functional properties of neutralizing Abs induced in US travelers with laboratory confirmed ZIKV infections.
Building on our discoveries about primary Ab responses to DENVs, we propose that people exposed to ZIKV as
a primary flavivirus infection develop type-specific neutralizing Abs that target quaternary structure envelope (E)
protein epitopes displayed on the viral surface (Specific Aim 2). While repeat infections with different DENV
serotypes induce durable cross DENV neutralizing Abs, it is unclear if this response can expand to neutralize
ZIKV. By analyzing Ab responses in people exposed to secondary DENV infections and DENV immune
individuals infected with ZIKV, we will determine the molecular mechanisms and structural features that promote
or restrict the breadth of Ab cross-neutralization between the DENV sero-complex and ZIKV (Specific Aim 3).
The importance of our studies is underscored by the disappointing results recently reported with tetravalent live
attenuated DENV vaccines to induce balanced cross-protective immunity to the 4 DENV serotypes. Our studies
are relevant to the successful design and evaluation of the next generation of safe and effective vaccines against
emerging flaviviruses. Moreover, patterns of cross-neutralizing and protective immunity between dengue and
Zika viruses may explain the explosive spread of ZIKVs in Latin America compared to Asia.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Structure based design of dengue subunit vaccines for inducing protective but not disease enhancing antibodies
-
批准号:10392040
-
项目类别:
-
资助金额:$72.32万
-
财政年份:2022
-
负责人:Aravinda M. DeSilva
-
依托单位:
Structure based design of dengue subunit vaccines for inducing protective but not disease enhancing antibodies
-
批准号:10612354
-
项目类别:
-
资助金额:$72.32万
-
财政年份:2022
-
负责人:Aravinda M. DeSilva
-
依托单位:
Core B: Shared Resource Core For Characterizing Antibody Responses To SARS-CoV-2 And Other Pathogenic Human Coronaviruses
-
批准号:10222242
-
项目类别:
-
资助金额:$52.88万
-
财政年份:2020
-
负责人:Aravinda M. DeSilva
-
依托单位:
Multiplex serological assays to support arbovirus diagnosis, surveillance and vaccines
-
批准号:10398179
-
项目类别:
-
资助金额:$41.36万
-
财政年份:2020
-
负责人:Aravinda M. DeSilva
-
依托单位:
Multiplex serological assays to support arbovirus diagnosis, surveillance and vaccines
-
批准号:10611391
-
项目类别:
-
资助金额:$41.36万
-
财政年份:2020
-
负责人:Aravinda M. DeSilva
-
依托单位:
Multiplex serological assays to support arbovirus diagnosis, surveillance and vaccines
-
批准号:10162498
-
项目类别:
-
资助金额:$41.36万
-
财政年份:2020
-
负责人:Aravinda M. DeSilva
-
依托单位:
Core B: Shared Resource Core For Characterizing Antibody Responses To SARS-CoV-2 And Other Pathogenic Human Coronaviruses
-
批准号:10688373
-
项目类别:
-
资助金额:$38.01万
-
财政年份:2020
-
负责人:Aravinda M. DeSilva
-
依托单位:
Structure based design of recombinant Zika virus antigens for serodiagnosis
-
批准号:9404101
-
项目类别:
-
资助金额:$23.33万
-
财政年份:2017
-
负责人:Aravinda M. DeSilva
-
依托单位:
Molecular Basis of Dengue Virus Neutralization by Human Antibodies
-
批准号:9206604
-
项目类别:
-
资助金额:$9.82万
-
财政年份:2016
-
负责人:Aravinda M. DeSilva
-
依托单位:
PRECLINICAL ASSAYS TO PREDICT TETRAVALENT DENGUE VACCINE EFFICACY
-
批准号:9901414
-
项目类别:
-
资助金额:$107.57万
-
财政年份:2016
-
负责人:Aravinda M. DeSilva
-
依托单位:
PRECLINICAL ASSAYS TO PREDICT TETRAVALENT DENGUE VACCINE EFFICACY
-
批准号:9153244
-
项目类别:
-
资助金额:$140.1万
-
财政年份:2016
-
负责人:Aravinda M. DeSilva
-
依托单位:
PROJECT 2: Linking Vaccine-Induced Antibody Responses to Protective or Disease Enhancing Immunity
-
批准号:10458129
-
项目类别:
-
资助金额:$37.68万
-
财政年份:2015
-
负责人:Aravinda M. DeSilva
-
依托单位:
PROJECT 2: Linking Vaccine-Induced Antibody Responses to Protective or Disease Enhancing Immunity
-
批准号:10244877
-
项目类别:
-
资助金额:$40.7万
-
财政年份:2015
-
负责人:Aravinda M. DeSilva
-
依托单位:
Molecular Basis of Dengue Virus Neutralization by Human Antibodies
-
批准号:8574001
-
项目类别:
-
资助金额:$47.3万
-
财政年份:2013
-
负责人:Aravinda M. DeSilva
-
依托单位:
Molecular Basis of Flavivirus Cross-Neutralization by Human Antibodies
-
批准号:10462622
-
项目类别:
-
资助金额:$57.16万
-
财政年份:2013
-
负责人:Aravinda M. DeSilva
-
依托单位:
Molecular Basis of Dengue Virus Neutralization by Human Antibodies
-
批准号:8713933
-
项目类别:
-
资助金额:$48.7万
-
财政年份:2013
-
负责人:Aravinda M. DeSilva
-
依托单位:
Molecular Basis of Dengue Virus Neutralization by Human Antibodies
-
批准号:8891931
-
项目类别:
-
资助金额:$48.7万
-
财政年份:2013
-
负责人:Aravinda M. DeSilva
-
依托单位:
Molecular Basis of Flavivirus Cross-Neutralization by Human Antibodies
-
批准号:10245040
-
项目类别:
-
资助金额:$57.16万
-
财政年份:2013
-
负责人:Aravinda M. DeSilva
-
依托单位:
Molecular Basis of Dengue Virus Neutralization by Human Antibodies
-
批准号:9111844
-
项目类别:
-
资助金额:$86.2万
-
财政年份:2013
-
负责人:Aravinda M. DeSilva
-
依托单位:
Dissecting the Human Antibody Response to Dengue Virus
-
批准号:8528904
-
项目类别:
-
资助金额:$33.45万
-
财政年份:2012
-
负责人:Aravinda M. DeSilva
-
依托单位:
海外基金